✨ Free AI Report
Altimmune, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Altimmune, Inc.
Company Research

Altimmune, Inc.: Business Overview, Financials & Competitive Analysis

Altimmune, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Pemvidutide's dual GLP-1/glucagon mechanism addresses high-value metabolic and liver disease markets with accelerated regulatory pathways. Altimmune demonstrates strong clinical progress with FDA Breakthrough Therapy designation and promising Phase 2b data for pemvidutide in a large market (MASH, obesity). Analyst consensus shows strong buy ratings with significant upside potential. However, as.

What is Altimmune, Inc.'s industry? Altimmune, Inc. (altimmune.com) operates in Biopharmaceutical - Clinical Stage Drug Development. AskCyborg classifies Altimmune, Inc. under Biopharmaceutical - Clinical Stage Drug Development in its company registry.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agoni...

7/ 10Strong

Cyborg Score thesis

Pemvidutide's dual GLP-1/glucagon mechanism addresses high-value metabolic and liver disease markets with accelerated regulatory...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Clinical Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Altimmune, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Altimmune, Inc.

AskCyborg analysts argue the bull and bear cases for Altimmune, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Altimmune, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Altimmune, Inc. Overview

Pro stress-test →

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis.

Strategic Profile

Pro stress-test →

Altimmune has received FDA Breakthrough Therapy Designation for its treatment pemvidutide, showing promising results in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). The company is set to enter a Phase 3 trial, aiming for accelerated approval, while analysts predict a substantial upside for the stock.

Competitive Landscape

Pro stress-test →

Altimmune competes in the high-growth GLP-1 agonist market against companies developing similar metabolic therapeutics. Key competitors include Viking Therapeutics, Zenas BioPharma, and larger pharma players entering obesity/MASH space. Altimmune's differentiation lies in its balanced dual glucagon/GLP-1 mechanism and Breakthrough Therapy designation, positioning it as a potential alternative to existing therapies.

Industry Context

Altimmune, Inc. operates in Biopharmaceutical - Clinical Stage Drug Development.

Key facts

Founded: 1997 · Headquarters: Gaithersburg, Maryland, US · Revenue: $20,000 (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Altimmune, Inc..

  • FDA Breakthrough Therapy Designation granted for pemvidutide in MASH, enabling accelerated approval pathway
  • Phase 3 trial enrollment underway following strong 48-week Phase 2b IMPACT trial efficacy and safety data
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026FDA End-of-Phase 2 meeting completed confirming Phase 3 trial parameters for MASH program
  • November 202548-week Phase 2b IMPACT trial data published demonstrating durable improvements in MASH markers
  • +1 moreTrack every material event for Altimmune, Inc. as it happens. Explore monitoring →
Get alerted when Altimmune, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GLP-1 Agonists for Obesity/MASHClinical-stage competitor developing dual GLP-1/GCG agonist→Metabolic Disease TherapiesDeveloping novel therapeutics for metabolic diseases→Established GLP-1 FranchisesMarket-leading obesity and MASH treatment providers→

Compare Altimmune, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Altimmune, Inc. operates in Biopharmaceutical - Clinical Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Clinical Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about Altimmune, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Altimmune, Inc. and its top competitor on Cyborg Score”
“What did Altimmune, Inc. do this quarter?”
“Is Altimmune, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Altimmune, Inc. do?+
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agoni...
What is Altimmune, Inc.'s Cyborg Score?+
Altimmune, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Altimmune, Inc.'s main competitors?+
Named competitors include GLP-1 Agonists for Obesity/MASH, Metabolic Disease Therapies, Established GLP-1 Franchises. The full competitive landscape is in the AskCyborg report.
How can I get the full Altimmune, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Altimmune, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Altimmune, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Clinical Stage Drug Development research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Aptorum Group Limited